Hemostemix Expands to the Dominican Republic
Hemostemix (TSXV: HEM) (OTC: HMTXF) has announced its expansion into the Dominican Republic with its ACP-01 therapy. The company has partnered with a team of cardiologists capable of treating 110 patients monthly, who have previously treated 200 ACP-01 recipients. Each ACP unit is priced at USD $37,000.
The treatment's efficacy is documented in a study published in Stem Cell Research and Therapy, involving 54 subjects treated for ischemic and non-ischemic dilated cardiomyopathy. The results showed significant improvements in ejection fraction, with increases of up to 47.1% in dilated cardiomyopathy patients and up to 27% in ischemic cardiomyopathy patients with an ejection fraction of 20% or less.
Hemostemix (TSXV: HEM) (OTC: HMTXF) ha annunciato la sua espansione nella Repubblica Dominicana con la sua terapia ACP-01. L'azienda ha stretto una partnership con un team di cardiologi in grado di trattare 110 pazienti al mese, che hanno precedentemente trattato 200 destinatari di ACP-01. Ogni unità di ACP ha un costo di USD $37,000.
L'efficacia del trattamento è documentata in uno studio pubblicato su Stem Cell Research and Therapy, che coinvolge 54 soggetti trattati per cardiomiopatia dilatativa ischemica e non ischemica. I risultati hanno mostrato significativi miglioramenti nella frazione d'eiezione, con aumenti fino al 47,1% nei pazienti con cardiomiopatia dilatativa e fino al 27% nei pazienti con cardiomiopatia ischemica con una frazione d'eiezione del 20% o meno.
Hemostemix (TSXV: HEM) (OTC: HMTXF) ha anunciado su expansión en la República Dominicana con su terapia ACP-01. La compañía se ha asociado con un equipo de cardiólogos que puede tratar a 110 pacientes mensualmente, quienes han tratado previamente a 200 receptores de ACP-01. Cada unidad de ACP tiene un precio de USD $37,000.
La eficacia del tratamiento está documentada en un estudio publicado en Stem Cell Research and Therapy, que involucra a 54 sujetos tratados por cardiomiopatía dilatada isquémica y no isquémica. Los resultados mostraron mejoras significativas en la fracción de eyección, con aumentos de hasta 47.1% en pacientes con cardiomiografía dilatada y hasta 27% en pacientes con cardiomiopatía isquémica con una fracción de eyección del 20% o menos.
헤모스테믹스 (TSXV: HEM) (OTC: HMTXF)는 도미니카 공화국에 ACP-01 치료법을 확장한다고 발표했습니다. 이 회사는 매달 110명의 환자를 치료할 수 있는 심장 전문의 팀과 파트너십을 맺었으며, 이들은 이전에 200명의 ACP-01 수혜자를 치료한 경험이 있습니다. 각 ACP 단위의 가격은 USD $37,000입니다.
치료의 효능은 줄기세포 연구 및 치료 저널에 발표된 연구에 문서화되어 있으며, 이 연구는 허혈성 및 비허혈성 확장형 심근병으로 치료받은 54명의 피험자를 포함합니다. 결과는 박출 분율에서 유의미한 개선을 보여주었으며, 확장형 심근병 환자에서는 최대 47.1%까지, 허혈성 심근병 환자에서는 박출분율 20% 이하인 경우 최대 27%까지 증가했습니다.
Hemostemix (TSXV: HEM) (OTC: HMTXF) a annoncé son expansion dans la République dominicaine avec sa thérapie ACP-01. La société s'est associée à une équipe de cardiologues capable de traiter 110 patients par mois, ayant déjà soigné 200 bénéficiaires d'ACP-01. Chaque unité ACP est au prix de USD $37,000.
L'efficacité du traitement est documentée dans une étude publiée dans Stem Cell Research and Therapy, impliquant 54 sujets traités pour cardiomyopathie dilatée ischémique et non ischémique. Les résultats ont montré des améliorations significatives de la fraction d'éjection, avec des augmentations pouvant atteindre 47.1% chez les patients atteints de cardiomyopathie dilatée et jusqu'à 27% chez les patients atteints de cardiomyopathie ischémique avec une fraction d'éjection de 20 % ou moins.
Hemostemix (TSXV: HEM) (OTC: HMTXF) hat seine Expansion in die Dominikanische Republik mit seiner ACP-01 Therapie angekündigt. Das Unternehmen hat sich mit einem Team von Kardiologen zusammengeschlossen, das in der Lage ist, monatlich 110 Patienten zu behandeln und bereits 200 ACP-01 Empfänger behandelt hat. Jede ACP-Einheit kostet USD $37,000.
Die Wirksamkeit der Behandlung ist in einer Studie dokumentiert, die in Stem Cell Research and Therapy veröffentlicht wurde und 54 Probanden umfasst, die aufgrund ischämischer und nicht-ischämischer dilatierter Kardiomyopathie behandelt wurden. Die Ergebnisse zeigten signifikante Verbesserungen der Ejektionsfraktion, mit Steigerungen von bis zu 47.1% bei Patienten mit dilatativer Kardiomyopathie und bis zu 27% bei Patienten mit ischämischer Kardiomyopathie und einer Ejektionsfraktion von 20% oder weniger.
- Treatment capacity of 110 patients per month at USD $37,000 per ACP unit
- Proven track record with 200 previous ACP-01 recipients
- Published clinical results showing up to 47.1% improvement in ejection fraction
- Expansion into new market (Dominican Republic)
- None.
Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company brings its revolutionary ACP-01 therapy back to the Dominican Republic.
Hemostemix has posted an update on Social Media, sharing an inside look at its latest initiative in the Dominican Republic, with a team of cardiologists who have the capacity to treat 110 patients per month. This team of cardiologists have previously treated 200 ACP-01 recipients. At USD
Seated left to right, Thomas Smeenk, Dr. Fernandez-de-Castro, Dr. Rosario Figueroa
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5065/239424_ee7b84f58433d830_002full.jpg
"This team's ACP-01 treatment results are published in Stem Cell Research and Therapy, the third study of 54 subjects treated for hardening of the arteries or expansion of the heart walls (ischemic and non ischemic dilated cardiomyopathy). ACP-01 demonstrated remarkable results, boosting ejection fraction percent by up to
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company and a leader in autologous stem cell therapy. With a patented blood-based stem cell therapeutics platform, Hemostemix is advancing regenerative medicine solutions, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors.
For more information, visit www.hemostemix.com.
Stock Information: (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0)
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239424
FAQ
What is the price per ACP-01 treatment unit for HMTXF's therapy?
How many patients can HMTXF's Dominican Republic facility treat monthly?
What are the clinical results of HMTXF's ACP-01 therapy for cardiomyopathy?
How many patients have previously received HMTXF's ACP-01 treatment in the Dominican Republic?
